Infliximab as a Therapy for Idiopathic Hypereosinophilic Syndrome

Isolated symptomatic cutaneous disease in hypereosinophilic syndrome

“…A recent case report documents the successful treatment of a patient with idiopathic HES with infliximab, a chimeric human‐mouse antibody for tumour necrosis factor. The exact mechanism of action in this context is unknown 14 …”

Informed consent and biological agents in rheumatology and internal medicine

“…38 Golimumab Uveitis, 39 refractory juvenile idiopathic arthritis-associated uveitis. 40 Infliximab Pityriasis rubra pilaris, 30 idiopathic hypereosinophilic syndrome, 41 cachexia in advanced pancreatic cancer patients, 42 refractory retinal vasculitis due to sarcoidosis, 43 cardiac sarcoidosis, 44 Takayasu arteritis, 45 refractory dermatomyositis, 46 steroid-resistant graft-versus-host disease, 47 complex regional pain syndrome, 48 hidradenitis suppurativa, 49 pyoderma gangrenosum, 50 Behçet's disease, 51 childhood refractory chronic uveitis, 26 refractory neuro-Behçet. 52 Anakinra Colchicine-resistant familial Mediterranean fever, 53 Schnitzler's syndrome, 54 Muckle-Wells syndrome, 55 acute gout, 56 hidradenitis suppurativa.…”

The hypereosinophilic syndromes: current concepts and treatments

“…Other agents employed in the therapy of HES include alemtuzumab, a monoclonal antibody reactive with CD52 (Dearden et al , 2002) and infliximab, a monoclonal antibody reactive with tumour necrosis factor (TNF‐α) (Taverna et al , 2007). Alemtuzumab has been utilized with success in one patient with lymphocytic HES and a CD3 − CD4 + clone (Pitini et al , 2004) and another with HES of Undefined Complex variant (Sefcick et al , 2004).…”

“…However, in the absence of carefully done clinical trials, its potential remains unknown. One patient with HES in the undefined/complex variant presenting with erythroderma responded to infliximab (Taverna et al , 2007).…”